A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck.
In a randomized prospective study of patients with advanced squamous cell carcinoma of the head and neck, treatment with MTX plus BCG and with MTX plus BCG plus INH produced no better response rate or survival time than treatment with MTX alone.
D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
D001500:BCG Vaccine; D003520:Cyclophosphamide; D007538:Isoniazid; D008727:Methotrexate